Research Article| Volume 25, ISSUE 6, P1411-1416, June 2016

Intracranial Stenting as a Rescue Therapy in Patients with Stroke-in-Evolution


      The feasibility and efficacy of intracranial stenting were evaluated for patients with a stroke-in-evolution after the time window for thrombolysis.


      Patients with symptomatic intracranial steno-occlusive disease with progressive or fluctuating symptoms were treated using intracranial stenting after the time window for hyperacute thrombolysis.


      Within the study period, we identified 10 patients (7 men, 62.5 ± 11.3 years old) who were eligible for inclusion. The median onset-to-arrival time was 5.8 hours (range: .6-144 hours), and the median onset-to-procedure time was 33 hours (range: 8-346 hours). Only 1 patient previously received intravenous thrombolysis using alteplase. The symptomatic occlusive artery was the right middle cerebral artery, left middle cerebral artery, and basilar artery in 3, 1, and 6 patients, respectively. The median initial National Institutes of Health Stroke Scale (NIHSS) score was 4 (range: 0-6), and the median NIHSS score measured immediately before the procedure was 8 (range: 4-26). All but 1 patient underwent successful angioplasty and stenting using a Wingspan stent. Reocclusion of the stented artery occurred in 1 patient, and his neurological status deteriorated to coma. A favorable outcome (modified Rankin Scale ≤2) at 3 months was noted in 7 patients (70%).


      Intracranial stenting could be considered an alternative strategy for treating patients with medically intractable stroke-in-evolution.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sacco R.L.
        • Kasner S.E.
        • Broderick J.P.
        • et al.
        An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 2064-2089
        • Holmstedt C.A.
        • Turan T.N.
        • Chimowitz M.I.
        Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment.
        Lancet Neurol. 2013; 12: 1106-1114
        • Pu Y.
        • Dou X.
        • Liu L.
        Natural history of intracranial atherosclerotic disease.
        Front Neurol. 2014; 5: 125
        • Ma Y.
        • Liu L.
        • Pu Y.
        • et al.
        Predictors of neurological deterioration during hospitalization: results from the Chinese Intracranial Atherosclerosis (CICAS) Study.
        Neurol Res. 2015; 37: 385-390
        • Ding D.
        Endovascular mechanical thrombectomy for acute ischemic stroke: a new standard of care.
        J Stroke. 2015; 17: 123-126
        • Kernan W.N.
        • Ovbiagele B.
        • Black H.R.
        • et al.
        Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2014; 45: 2160-2236
        • Chimowitz M.I.
        • Lynn M.J.
        • Derdeyn C.P.
        • et al.
        Stenting versus aggressive medical therapy for intracranial arterial stenosis.
        N Engl J Med. 2011; 365: 993-1003
        • Britton M.
        • Roden A.
        Progression of stroke after arrival at hospital.
        Stroke. 1985; 16: 629-632
        • Karepov V.G.
        • Gur A.Y.
        • Bova I.
        • et al.
        Stroke-in-evolution: infarct-inherent mechanisms versus systemic causes.
        Cerebrovasc Dis. 2006; 21: 42-46
        • Castillo J.
        Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment.
        Cerebrovasc Dis. 1999; 9: 1-8
        • Ozdemir O.
        • Beletsky V.
        • Chan R.
        • et al.
        Thrombolysis in patients with marked clinical fluctuations in neurologic status due to cerebral ischemia.
        Arch Neurol. 2008; 65: 1041-1043
        • Seo W.K.
        • Seok H.Y.
        • Kim J.H.
        • et al.
        C-reactive protein is a predictor of early neurologic deterioration in acute ischemic stroke.
        J Stroke Cerebrovasc Dis. 2012; 21: 181-186
        • Ois A.
        • Martinez-Rodriguez J.E.
        • Munteis E.
        • et al.
        Steno-occlusive arterial disease and early neurological deterioration in acute ischemic stroke.
        Cerebrovasc Dis. 2008; 25: 151-156
        • Kim J.T.
        • Kim H.J.
        • Yoo S.H.
        • et al.
        MRI findings may predict early neurologic deterioration in acute minor stroke or transient ischemic attack due to intracranial atherosclerosis.
        Eur Neurol. 2010; 64: 95-100
        • Yong S.W.
        • Bang O.Y.
        • Lee P.H.
        • et al.
        Internal and cortical border-zone infarction: clinical and diffusion-weighted imaging features.
        Stroke. 2006; 37: 841-846
        • Wong K.S.
        • Gao S.
        • Chan Y.L.
        • et al.
        Mechanisms of acute cerebral infarctions in patients with middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli monitoring study.
        Ann Neurol. 2002; 52: 74-81
        • Chimowitz M.I.
        • Lynn M.J.
        • Howlett-Smith H.
        • et al.
        Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
        N Engl J Med. 2005; 352: 1305-1316
        • Shuaib A.
        • Bornstein N.M.
        • Diener H.C.
        • et al.
        Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial.
        Stroke. 2011; 42: 1680-1690
        • Ginsberg M.D.
        • Palesch Y.Y.
        • Hill M.D.
        • et al.
        High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.
        Lancet Neurol. 2013; 12: 1049-1058
        • Zaidat O.O.
        • Fitzsimmons B.F.
        • Woodward B.K.
        • et al.
        Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial.
        JAMA. 2015; 313: 1240-1248
        • Levy E.I.
        • Siddiqui A.H.
        • Crumlish A.
        • et al.
        First Food and Drug Administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization in acute ischemic stroke).
        Stroke. 2009; 40: 3552-3556